Remove 2023 Remove Heart Failure Remove Preserved Ejection Fraction
article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

DAIC

announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our healthcare system.

article thumbnail

Differences in heart failure with preserved ejection fraction management between care providers: an international survey

European Journal of Heart Failure

Differences in heart failure with preserved ejection fraction (HFpEF) management across medical specialties. Methods and results An independent web-based survey was distributed globally between May and July 2023. A large majority of HFpEF patients are cared by non-cardiologists.

article thumbnail

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF

Circulation: Heart Failure

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010633, November 1, 2023. BACKGROUND:Heart failure with preserved ejection fraction is associated with significant functional limitations, yet treatments for improving exercise performance have been elusive.

article thumbnail

Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta?analysis

Journal of Cardiovascular Electrophysiology

Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF).

article thumbnail

MMP-2 Associates With Incident Heart Failure and Atrial Fibrillation: The ARIC Study

Circulation: Heart Failure

Circulation: Heart Failure, Volume 16, Issue 11 , Page e010849, November 1, 2023. Mediation of the association between MMP-2 and HF was assessed by censoring participants who developed AF or coronary heart disease before HF. 1.81]), incident HF with preserved ejection fraction (1.44 [95% CI, 1.07–1.94]),

article thumbnail

REBALANCE-HF: Splanchnic Nerve Ablation For Volume Redistribution in HFpEF

American College of Cardiology

Splanchnic ablation for volume management (SAVM) in heart failure with preserved ejection fraction (HFpEF) was discussed as a late-breaking trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 in Cleveland, Ohio.